Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option

References

• O'Brien S, Del Giglio A, Keating M. Advances in the biology and treatment of B cell chronic lymphocytic leukemia. Blood 1995;85:306–18.
   Google Scholar
• Dreger B, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M, Schmitz N, Dohner H. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood 2004;103:2850–8.
   Google Scholar
• Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D. Guidelines of the diagnosis and management of chronic lymphocytic leukemia. Br J Haema-tol 2004;125:294–317.
   Google Scholar
• Lennert K, Mohri N, Stein H, Kaiserling E, Mueller-Hermelink HK. Malignant lymphomas other than Hodgkins disease. Berlin: Springer; 1978. p 119–29.
   Google Scholar
• Meinhardt G, Wendtner CM, Hallek M. Molecular patho-genesis of chronic lymphocytic leukemia: factors and signaling pathways regulation cell growth and survival. J Mol Med 1999;77:282–93.
   Google Scholar
• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of different feather. J Chin Oncol 1999;17:399–408.
   Google Scholar
• Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic abberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–16.
   Google Scholar
• Pezzella T, Tse AG, Cordell JL, Pulford KA, Garter KC, Mason DY. Expression of the bc1-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137:225–32.
   Google Scholar
• Kitada S, Andersen J, Akar S, Zapata JM, Takayarna S, Krajewski S, Wang HG, Zang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC. Expression of apoptosis regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponsiveness. Blood 1998;91:3379–89.
   Google Scholar
• Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. Antigen receptor nonresponsiveness in chronic lymophocytic leukemia B cells. Blood 1995;86:1090–7.
   Google Scholar
• Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, Jaffe ES, Raffeld M. Mantle cell lymphomas lack expression of p27kip 1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998;153: 175–82.
   Google Scholar
• Pileri SA, Ascani S, Sabattini E, Fraternali-Orcioni G, Poggi S, Piccioli M, Piccaluga PP, Gamberi B, Zinzani PL, Leoncini L, Falini B. The pathologist's view point. Part I-indolent lymphomas. Hematologica 2000;85:1291–307.
   Google Scholar
• Schmidt C, Isaacson PG. Proliferation centers in B-cell malignant lymphoma, lymphocytic (B-CLL): an immuno-phenotypic study. Histopathology 1994;24:445–51.
   Google Scholar
• Ambrosini G, Adida C, Alteri DC. A novel anti-apoptotic gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–21.
   Google Scholar
• Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and cell cycle checkpoint by survivin. Nature 1997;396:580–4.
   Google Scholar
• Vehovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27 in chronic lymphocytic leukemia. Blood 1998;91: 4694–700.
   Google Scholar
• Decker T, Flohr T, Trautmann P, Aman MJ, Holter W, Majdic 0, Huber C, Peschel C. Role of accessory cells in cytokine production by T-cells in chronic lymphocytic leukemia. Blood 1995;86:1115–23.
   Google Scholar
• Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, Ruffling N, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4 +, CD4OL + T cells by producing CCL22. Eur J Immunol 2002;32: 1403–13.
   Google Scholar
• Fluckinger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992;80:3173–81.
   Google Scholar
• Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhances apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukemia. Br J Haematol 1999;106:995–1004.
   Google Scholar
• Kay NE, Han L, Bone N, Williams G. Interleukin 4 content in chronic lymphocytic leukemia (CLL) B cells and blood CD8 + T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol 2001;112:760–7.
   Google Scholar
• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of different feather. J Chin Oncol 1999;17:399–408.
   Google Scholar
• Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells are rescued from apoptosis by contact with bone marrow stromal cells. Blood 1998;91:2387–96.
   Google Scholar
• Vincent AM, Cawley JC, Burthem J. Integrin function in chronic lymphocytic leukemia. Blood 1996;87:4780–8.
   Google Scholar
• Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;96: 2655–63.
   Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996;274:231–4.
   Google Scholar
• Hirama T, Koeffler P. Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841–54.
   Google Scholar
• Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky P. Activation of human B cells by phosphorothioate oligonu-cleotides. J Chin Invest 1996;98: 1119–29.
   Google Scholar
• Hartmann G, Krieg AM. Mechanism and function of newly identified CpG DNA motif in human primary B cells. J Immunol 2000;164:944–53.
   Google Scholar
• Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, Peschel C. Immunostimulatory CpG-oligonu-cleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients. Blood 2000;95:999–1006.
   Google Scholar
• Decker T, Schneller F, Hipp S, Miething C, Jahn T, Duyster J, Peschel C. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk)4 and the cdk inhibitor p27. Leukemia 2002;16: 327–34.
   Google Scholar
• Wagner EF, Hleb M, Hanna N, Sharma S. A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of 11-2, IL-4 or IL-10-mediated B cell prolifera-tion. J Immunol 1998;161:1123–31.
   Google Scholar
• Blanchard DA, Affredou MT, Vazquez A. Modulation of the p27Kipl cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation. J Immunol 1997;160: 3054–61.
   Google Scholar
• Klein A, Miera 0, Bauer 0, Golfier S, Schriever F. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000;14:40–6.
   Google Scholar
• Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification of at least two distinct cyclin- cdk complexes. Mol Cell Biol 1998;18:753–61.
   Google Scholar
• Decker T, Hipp S, Hahntow I, Schneller F, Peschel C. Expression of cyclin E in resting and activated B-chronic lymphocytic leukemia cells: cyclin E/cdk-2 as potential therapeutic target. Br J Haematol 2004;125: 141–8.
   Google Scholar
• Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, Peschel C. Rapamycin-induced G1 -arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A and survivin. Blood 2003; 101:278–85.
   Google Scholar
• Brown EJ, Albers MW, Shin TB, Ichikawa I, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1 - arresting rapamycin-receptor complex. Nature 1994; 369:756–8.
   Google Scholar
• Gingras AC, Raught B, Sonnenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807–26.
   Google Scholar
• Rosenwald IB, Kaspar R, Rousseau D, Gehrke L, Leboulch P, Chen JJ, Schmidt EV, Sonenberg N, London IM. Eukaryotic translation initiation factor 4E regulates expres-sion of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995;270: 21176–80.
   Google Scholar
• Shantz LM, Pegg AE. Overproduction of ornithine decar-boxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res 1994;54:2313–6.
   Google Scholar
• Sonenberg N, Gingras AC. The mRNA 5' cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998;10:268–75.
   Google Scholar
• Mendez R, Myers MG, White ME, Rhoads RE. Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and PI3K. Mol Cell Biol 1996;16:2857–64.
   Google Scholar
• Jiang H, Coleman J, Miskimins R, Minskimins WK. Expression of constitutively active 4EBP-1 enhances p27kipl expression and inhibits proliferation of MCF7 breast cancer cells. Cancer Cell Int 2003;3:2.
   Google Scholar
• Law B, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor beta-induced growth arrest in non-transformed, oncogenes-transformed and hu-man cancer cells. Mol Cell Biol 2002;22:8184–98.
   Google Scholar
• Jefferies HB, Fumgalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5' TOP mRNA translation through inhibition of p7056K. EMBO J 1997;16:3693–704.
   Google Scholar
• Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci 1994;91:11477–81.
   Google Scholar
• Volarevic S, Thomas G. Role of S6 phosphorylation and S6kinase in cell growth. Prog Nuclei Acid Res Mol Biol 2001;65:101–27.
   Google Scholar
• Dennis PB, Pullen N, Kozma SC, Thomas G. The principal rapamycin-sensitive p70S6kinase phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin sensitive kinase. Mol Cell Biol 1996;16:6242–51.
   Google Scholar
• Bjornski MA, Houghton PJ. The TOR pathway; a target for cancer therapy. Nat Rev Cancer 2004;4:335–48.
   Google Scholar
• Vezina C, Kudelski A, Shegal SN. Rapamycin (AY-22989), a new antifungal antibiotic. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28: 721–6.
   Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanisms of action immunosuppressive effects results from blockage of signal transduction and inhibition of cell cycle progression. Chin Biochem 1998;31:335–40.
   Google Scholar
• Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981;8:63–87.
   Google Scholar
• Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22989) against transplanted tumors. J Antibiot (Tokyo) 1984;37: 1231–7.
   Google Scholar
• Brown EJ, Albers MW, Shin TB, Ichikawa I, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1 - arresting rapamycin-receptor complex. Nature 1994; 269:756–8.
   Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991;253:1231–7.
   Google Scholar
• Siekierka jj, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341: 755–7.
   Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinosito1-3 kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489–501.
   Google Scholar
• Sorrells DL, Meschonat C, Black D, Li BD. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. J Surg Res 1999;85: 37–42.
   Google Scholar
• Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci 2001;98: 10314–9.
   Google Scholar
• Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CI-779, a novel mTOR kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Chin Oncol 2004;22:909–18.
   Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valentine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH, Bernhardt P. RAD B253 Study Group. Everolismus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349: 847–58.
   Google Scholar
• Hoyer PF, Ettenger R, Kovarik JM, Webb NJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H. Everolimus Pediatric Study Group. Everolimus in pediatric de nova renal transplant patients. Transplantation 2003;75:2082–5.
   Google Scholar
• Schuler W, Sedarni R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes H, Schreier MH. SDZ RAD, a new rapamycin derivate: pharmacological properties in vitro and in vivo. Transplantation 1997; 64:36–42.
   Google Scholar
• Farb A, John M, Acampado E, Frank D, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointima growth. Circulation 2002;106:2379–84.
   Google Scholar
• Levy GA, Grant D, Paradis K, Campestrini J, Smith T, Kovarik JM. Pharmacokinetics and tolerability of 40-0-0-(2-hydroxyethyl)ramamycin in de novo liver transplant recipi-ents. Transplantation 2001;71:160–3.
   Google Scholar
• Muthukkumar S, Ramesh TM, Bonada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995;60:264–70.
   Google Scholar
• Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H, Houghton PJ. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/ p2 1 cipl. Mol Cell 2003;11: 1491–1501.
   Google Scholar
• Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Carbot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580–9.
   Google Scholar
• Li HL, Davis W, Pure E. Suboptimal cross-linking of antigen receptor induces Syk-dependent activation of p70S6 kinase through protein-kinase C and PI-3 kinase. J Biol Chem 1999;274: 9812–20.
   Google Scholar
• Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor )3-induced growth arrest in non-transformed, oncogene-transformed and hu-man cancer cells. Mol Biol Cell 2002;22: 8184–98.
   Google Scholar
• Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. IL-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27Kipl. Blood 2001;98:1524 — 31.
   Google Scholar
• Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. IL-2 mediated elimination of p27Kip cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372: 570–3.
   Google Scholar
• Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M, Caligaris-Cappio F. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97: 2777— 83.
   Google Scholar
• Kanwar Jr, Shen WP, Rupinder KK, Berg RW, Krissansen GW. Effects of survivin antagonists on growths of established tumors in B7-1 immunogene therapy. J Natl Cancer Inst 2001;93: 1541–52.
   Google Scholar
• Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Chin Invest 2001;108:981–90.
   Google Scholar
• Dumont FJ, Staruch KJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144: 251 — 8.
   Google Scholar
• Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. The Rapamune US Study Group. Lancet 2000;356:194 — 202.
   Google Scholar
• Shapiro AM, Lakey Jr, Ryan EA, Korbutt GS, Thoth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplanta-tion in seven patients with type I diabetes mellitus using a glucocorticoid free immunosuppressive regimen. N Engl J Med 2000;343:230— 8.
   Google Scholar
• Serrano D, Monteiro J, Allen SL, Kolitz J, Schulman P, Lichtman SM, Buchbinder A, Vinciguerra VP, Chiorazzi N, Gregersen PK. Clonal expansion within the CD4 + CD57 + and CD8 + CD57 + T cell subsets in chronic lymphocytic leukemia. J Immunol 1997;158:1482–9.
   Google Scholar
• Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000;14:1414 — 8.
   Google Scholar
• Duensing S, Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood 1995;85:1978–80.
   Google Scholar
• Chen H, Treweeke AT, West DC, Till KJ, Cawley JC, Zuzel M, Toh CH. In vitro and in vivo production of vascular endothelial growth factor in B-cell chronic lymphocytic leukemia cells. Blood 2000;96:3181–7.
   Google Scholar
• Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, Cavazzini F, Squillace R, Mirabelli R, Digiesi G. Increased serum levels of MMP-9 predict clinical outcome of patients with early B-CLL. Eur J Haematol 2003;70:373 —8.
   Google Scholar
• Guba M, Breitenbach P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler E. Rapamycin inhibits primary and metastatic growth by antiangiogensis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128–35.
   Google Scholar
• Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-KB activity and apoptosis in chronic lymphocytic leukaemia. J Immunol 2000;164:2200— 6.
   Google Scholar
• Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukaemia contain signal transdu-cer and activator of transcription (STAT)1 and STAT3 constitutively phosphorylated on serine residues. J Chin Invest 1997;100: 3140–8.
   Google Scholar
• Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, Decker T. Constitutively activated PI 3-K is involved in the defect of apoptosis in B-CLL: association with PCK-S. Blood 2002;100: 3741–8.
   Google Scholar